Building Canadian capacity for CAR-T cells in relapsed/refractory acute lymphoblastic leukaemia: a retrospective cohort study

Br J Haematol. 2020 Oct;191(1):e14-e19. doi: 10.1111/bjh.16940. Epub 2020 Jul 20.

Roy Khalife^{1

2}, Joshua Montroy³, Emma J M Grigor², Dean A Fergusson^{2

4

5}, Harold Atkins^{4

6}, Matthew Seftel⁷, Justin Presseau^{3

5}, Kednapa Thavorn^{3

5}, Robert A Holt⁸, Kevin Hay⁹, Manoj M Lalu^{3

10}, Natasha Kekre^{3

4}

¹ Department of Medicine, The Ottawa Hospital, Ottawa, Ontario, Canada.
² Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada.
³ Clinical Epidemiology Program, Ottawa Hospital Research Institiute, Ottawa, Ontario, Canada.
⁴ Blood and Marrow Transplant Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.
⁵ School of Epidemiology and Pubic Health, University of Ottawa, Ottawa, Ontario, Canada.
⁶ Cancer Therapeutic Program, Ottawa Hospital Research Institute, Ontario, Ottawa, Canada.
⁷ Department of Internal Medicine, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Canada.
⁸ Michael Smith Genome Sciences Centre, British Columbia Cancer Agency, Vancouver, British Columbia, Canada.
⁹ Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
¹⁰ Department of Anesthesiology and Pain Medicine, The Ottawa Hospital, Ontario, Ottawa, Canada.

No abstract available

Keywords: CAR-T cell therapy; Tisagenlecleucel; acute lymphoblastic leukemia; cellular immunotherapy; cohort study.

Publication types